🔗 Share this article

Ministers and senior MPs have raised concerns that the United Kingdom's recent agreements with Washington are "lacking a solid foundation." This follows revelations that a recently announced deal on medicines, which commits to zero tariffs in exchange for the NHS increasing its costs, lacks any detailed agreement beyond vague headline terms contained within government press releases.

An Agreement in Principle Only

The deal on drug tariffs, described as a "significant" achievement, is still an "broad understanding" without a signed legal text. It has been highlighted that the press releases from the UK and US governments present the deal in divergent terms. The British version celebrates securing "zero per cent tariffs" as a unique achievement, while the American announcement concentrates on the expectation for the NHS to pay significantly more for new medications.

"We face a genuine possibility that the UK government has made commitments to raise drug prices in return for only a assurance from President Trump," commented David Henig, a trade expert. "It is documented he has a tendency for not following through on agreements."

A Pattern of Unreliability

Anxieties have been intensified by Washington's action to pause the major technology agreement, which was previously described as "a huge leap forward" in the bilateral relationship. The US cited a insufficient movement from the UK on lowering trade barriers as the reason for the pause.

Additionally, concessions promised for British farmers as part of an initial accord have still not been formally signed off by the US, despite a fast-approaching January deadline. "Our understanding is that the US has not finalized the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

In confidential discussions, ministers have voiced worries that the government's agreements with the US are flimsy and unreliable. One minister described the series of agreements as "resting on shaky ground," while another characterized the situation as the "current reality" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, a senior MP on the health committee, argued: "Perhaps most shocking than Trump's temper tantrums is the UK government's credulous faith that his administration is a reliable partner. The NHS is not a bargaining chip."

A Mixed Picture of Success and Setback

Ministry sources have sought to reduce the possibility of the US withdrawing from the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been pushing for the agreement, desiring stability on imports and pricing, making it less abstract than the paused tech deal.

Officials acknowledge that unpredictability is inherent in dealing with the Trump administration. However, they argue that the UK has achieved real benefits for businesses, such as reduced duties on automobiles compared to other nations. "Securing 25% steel tariffs, which is more favorable than the rate for the rest of the world, is a concrete advantage," one official said.

However, issues have arisen in carrying out the May tariff agreement. Promised access for British beef have yet to be finalized, and the assurance to "eliminate duties on UK metals" has remains unmet, with tariffs remaining at 25%.

Moving forward, the two sides have planned to recommence talks on the suspended digital agreement in January, following what were described as "productive" meetings between UK and US officials in Washington.